Adaptive Biotechnologies Corporation (ADPT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Adaptive Biotechnologies (ADPT) Q2 2026: Serial Testing Pull-Through Rises to 75%, Unlocking MRD Upside
  July 30, 2026
• Adaptive Biotechnologies (ADPT) Q4 2025: MRD Revenue Jumps 46% as ASP and Volume Tailwinds Strengthen
  June 15, 2026
• Adaptive Biotechnologies (ADPT) Q1 2026: MRD Revenue Jumps 53% as Community and Blood-Based Testing Hit Milestones
  May 06, 2026
• Adaptive Biotechnologies (ADPT) Q3 2025: MRD Revenue Jumps 52% as Clinical Volume and ASPs Accelerate
  November 06, 2025
• Adaptive Biotechnologies (ADPT) Q2 2025: MRD Revenue Jumps 42% as EMR Integration Accelerates Community Penetration
  August 06, 2025
• Adaptive Biotechnologies (ADPT) Q1 2025: ClonoSeq Volume Climbs 36% as EMR Integrations Accelerate
  July 04, 2025
• Adaptive Biotechnologies (ADPT) Q3 2024: MRD Revenue Jumps 52% as ASP and Pharma Momentum Accelerate
  November 07, 2024
• Adaptive Biotechnologies (ADPT) Q2 2024: MRD Revenue Up 36% as Pharma Bookings and Cost Discipline Reshape Trajectory
  August 01, 2024
• Adaptive Biotechnologies (ADPT) Q1 2024: MRD Revenue Jumps 52% as FDA, Pricing Tailwinds Build
  May 07, 2024
• Adaptive Biotechnologies (ADPT) Q4 2023: MRD Clinical Revenue Jumps 56%, Margin Levers Set for 2025 Profitability
  February 14, 2024
• Adaptive Biotechnologies (ADPT) Q3 2023: MRD Clinical Volumes Up 56%, Strategic Review Signals Business Split
  November 09, 2023

Browse all companies